Amgen Phase 3 Repatha data shows reduced need for apheresis
Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »